Drug Trial Radar · NCT07925983
A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 13, 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity and safety following trosunilimab SC and trosunilimab IV doses in healthy adult participants.
Conditions
- Healthy Volunteer
Interventions
TrosunilimabDrug
Subcutaneous (SC) Injection
TrosunilimabDrug
Intravenous (IV) Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Serum Concentration (Cmax) of trosunilimabTime frame: Up to 7 Days
- Time to Cmax (Tmax) of trosunilimabTime frame: Up to 7 Days
- Concentration at Week 4 (Cwk4) of trosunilimabTime frame: Week 4
- Area under the serum concentration-time curve from Week 0 to 4 (AUC0-4wk) of trosunilimabTime frame: Weeks 0 to 4
- Number of Participants Experiencing Adverse EventsTime frame: Up to 140 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 286224
Grayslake, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.